Palbociclib — Taking Breast-Cancer Cells Out of Gear  

Oleh:

Carey, Lisa A. ; Perou, Charles M.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 373 no. 03 (Jul. 2015), page 273-274.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Palbociclib is a first-in-class inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). In some but not all cell types, these proteins regulate the transition from the G1 phase to the S phase of the cell cycle. CDK4 and CDK6 regulate proliferation in some types of epithelial cells, including estrogen-receptor–positive luminal cells.1 In estrogen-receptor–positive breast cancers, estrogen induces CDK4 and CDK6 activity, leading to hyperphosphorylation of RB (the gene encoding retinoblastoma protein) and promotion of cell-cycle traversal; this is the rationale for testing CDK4 and CDK6 inhibitors in estrogen-receptor–positive breast cancer.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali